Femoral Arterial Cannulation in Pediatrics
Launched by AMERICAN UNIVERSITY OF BEIRUT MEDICAL CENTER · Jul 8, 2025
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different ways to place a small tube (called a cannula) into the femoral artery—a large blood vessel in the groin area—in infants and children undergoing heart surgery. The goal is to see which method helps anesthesia doctors perform this procedure faster and more safely during surgery. One method uses a special ultrasound-guided technique called MDNTP-SAOP, while the other uses a more traditional ultrasound approach called C-SAOP. Researchers want to know which technique takes less time on the first attempt and causes fewer complications.
Children under 12 years old who have congenital heart disease and are scheduled for planned heart surgery may be eligible to join, as long as they are generally stable and don’t already have a line in the femoral artery. During the surgery, anesthesia doctors will use one of the two methods to place the cannula, and the team will record how long it takes, how many tries are needed, and if any problems happen afterward, such as bruising, infection, or blood flow issues in the leg. The study is not yet recruiting participants but aims to help improve the safety and efficiency of care for children having heart surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Infants and children under 12 years of age.
- • American Society of Anesthesiologist (ASA) physical status II-IV.
- • Patients with congenital heart disease undergoing cardiac surgery who do not have existing arterial line access.
- Exclusion Criteria:
- • Need for emergency surgery.
- • Hemodynamic instability.
About American University Of Beirut Medical Center
The American University of Beirut Medical Center (AUBMC) is a leading academic medical institution in the Middle East, dedicated to advancing healthcare through innovative research, education, and clinical excellence. As a prominent sponsor of clinical trials, AUBMC integrates cutting-edge scientific inquiry with patient-centered care to enhance therapeutic options and improve health outcomes. With a commitment to ethical standards and regulatory compliance, AUBMC collaborates with multidisciplinary teams to conduct rigorous trials that contribute to the global medical knowledge base and address critical health challenges in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Amro Khalili, MD
Principal Investigator
American University of Beirut Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported